MedPath

Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule for Severe Alcohol Addiction

Not Applicable
Conditions
Addiction
Interventions
Other: Deep brain stimulation
Other: Placebo
Registration Number
NCT01658592
Lead Sponsor
Guodong Gao
Brief Summary

The main objective of this study is to assess the efficacy of bilateral deep brain stimulation (DBS) of the nucleus accumbens (NAc) and the ventral anterior internal capsule (VC) as a novel treatment in severe alcohol addiction. The included patients have been treated so far with drugs that inhibits alcohol, or psychological behavior training.

Our hypothesis is that bilateral NAc-VC DBS will significantly reduce the craving for alcohol and thus enable the patients to decrease their alcohol intake substantially.

Detailed Description

The nucleus accumbens (NAc) is considered associating with addiction. The ventral anterior internal capsule(VC) is proved a effective target to obsessive compulsive disorder(OCD). Like other addiction behaviors most alcohol addicts contain obsessive compulsive symptom. We explored an operation method, that is, in the Leksell stereotactic positioning system take VC as the point of entry, take NAc as the point of target, then make sure that the distance between entry and target points are included in the four contacts of electrode of DBS. When stimulator is ON the investigators can adjust parameters so that the coverage of electrode contains both Vc and NAc. The investigators suppose that bilateral NAc-VC DBS will significantly reduce the craving for alcohol and thus enable the patients to decrease their alcohol intake substantially.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Age > 18 years
  • Long lasting alcohol addiction (fulfilled diagnostic-criteria according to DSM-IV,ICD-10)
  • At least one detoxication-treatment without a long-term period of abstinence has already taken place
  • Long-term inpatient treatment to support abstinence have occurred
  • Free patient's decision / Informed Consent (existing comprehensive ability in meaning, methodology and execution of the study and ability of acceptance)
  • If prior medication, stable dosage of psychopharmacological drugs over the last three months, which shall, after checking be retained during the study
Exclusion Criteria
  • Hospitalization for psychotic symptoms
  • Clinical relevant psychiatric comorbidity (such as schizophrenic psychoses, bipolar affective diseases, severe personality disorder, and so on. And diagnosed by criteria according to DSM-IV,ICD-10)
  • Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/ heart defibrillator
  • Current and in the last six months existent paranoid-hallucinated symptomatology
  • Foreign aggressiveness in the last six months
  • Verbal IQ < 85 (evaluated with the Wechsler Adult Intelligence Scale- Chinese Revised (WAIS-CR)
  • Stereotactic respectively neurosurgical intervention in the past
  • Other neurological diseases
  • Contraindications of a stereotactic operation, e.g. increased bleeding-disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases)
  • Serious and instable organic diseases (e.g. instable coronal heart disease)
  • tested positively for HIV
  • pregnancy and/or lactation

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Placebo ADeep brain stimulationStimulator setting is OFF
Placebo APlaceboStimulator setting is OFF
NAC-VC Deep Brain StimulationDeep brain stimulationThe contractors located in NAc and VC are ON at the same time
NAC-VC Deep Brain StimulationPlaceboThe contractors located in NAc and VC are ON at the same time
Placebo BDeep brain stimulationThe contractor located in NAc is on
Placebo BPlaceboThe contractor located in NAc is on
Placebo CDeep brain stimulationThe contactor located in VC is on
Placebo CPlaceboThe contactor located in VC is on
Primary Outcome Measures
NameTimeMethod
Reduction of Alcohol7 months

Reduction of the dosage of alcohol(all kinds of liquor were converted into pure alcohol) comparing baseline and the particular ward rounds during and at the end of the crossover-design.

Secondary Outcome Measures
NameTimeMethod
Craving7 months

10-point visual analog scale (VAS) of craving

Trial Locations

Locations (1)

Department of neurosurgery, Tangdu Hospital

🇨🇳

Xi'an, Shaanxi, China

Department of neurosurgery, Tangdu Hospital
🇨🇳Xi'an, Shaanxi, China
Gao G Dong, Doctor
Contact
+86 29-84777435
gguodong@fmmu.edu.cn
Wang X Lian, Doctor
Sub Investigator
© Copyright 2025. All Rights Reserved by MedPath